TGFBR2 and prostate adenocarcinoma: MET and TGFBR2 gene expressions were found to positively correlate in several other tumor entities, such as prostate adenocarcinoma, thymoma, glioblastoma, head and neck squamous cell carcinoma, testicular germ cell tumors, and esophageal carcinoma (Fig. S3D–I).